Cullinan Therapeutics (CGEM) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Cullinan Therapeutics (NASDAQ: CGEM) in the last few weeks:

• 6/14/2026 – Cullinan Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/11/2026 – Cullinan Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $37.00 price target on the stock.
• 6/8/2026 – Cullinan Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $30.00 price target on the stock.
• 6/6/2026 – Cullinan Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/19/2026 – Cullinan Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $38.00 price target on the stock.
• 5/9/2026 – Cullinan Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/8/2026 – Cullinan Therapeutics had its price target raised by Wedbush from $36.00 to $37.00. They now have an “outperform” rating on the stock.
• 5/4/2026 – Cullinan Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $38.00 price target on the stock.
• 4/28/2026 – Cullinan Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $38.00 price target on the stock.
• 4/28/2026 – Cullinan Therapeutics had its price target raised by HC Wainwright from $27.00 to $30.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In related news, insider Jennifer Michaelson sold 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $14.62, for a total transaction of $116,960.00. Following the transaction, the insider directly owned 166,844 shares of the company’s stock, valued at approximately $2,439,259.28. This represents a 4.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 8.60% of the company’s stock.

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.